RWC Asset Advisors US LLC Takes Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

RWC Asset Advisors US LLC bought a new stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,174 shares of the company’s stock, valued at approximately $569,000. Dr. Reddy’s Laboratories makes up about 0.0% of RWC Asset Advisors US LLC’s investment portfolio, making the stock its 19th biggest position.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. increased its holdings in Dr. Reddy’s Laboratories by 15.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,673,126 shares of the company’s stock worth $111,882,000 after acquiring an additional 218,605 shares in the last quarter. Aikya Investment Management Ltd purchased a new stake in Dr. Reddy’s Laboratories in the 4th quarter worth $75,850,000. Vanguard Group Inc. increased its holdings in Dr. Reddy’s Laboratories by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,048,152 shares of the company’s stock worth $70,090,000 after acquiring an additional 20,341 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Dr. Reddy’s Laboratories by 26.9% during the 3rd quarter. Acadian Asset Management LLC now owns 270,260 shares of the company’s stock worth $18,066,000 after purchasing an additional 57,293 shares during the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC boosted its stake in Dr. Reddy’s Laboratories by 47.5% during the 3rd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 250,788 shares of the company’s stock worth $16,770,000 after purchasing an additional 80,784 shares during the last quarter. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

RDY traded up $0.53 on Friday, hitting $74.55. 216,239 shares of the company’s stock were exchanged, compared to its average volume of 171,372. The firm has a 50-day moving average price of $74.17 and a 200-day moving average price of $70.43. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. The stock has a market cap of $12.44 billion, a price-to-earnings ratio of 19.67, a P/E/G ratio of 1.85 and a beta of 0.58. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $53.12 and a fifty-two week high of $77.72.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.11. The firm had revenue of $867.00 million for the quarter, compared to analysts’ expectations of $827.81 million. Dr. Reddy’s Laboratories had a net margin of 19.26% and a return on equity of 20.97%. As a group, equities analysts anticipate that Dr. Reddy’s Laboratories Limited will post 3.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Barclays lifted their target price on shares of Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, January 29th. StockNews.com raised shares of Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 5th. Finally, Jefferies Financial Group cut shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $80.00.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.